Moleculin Biotech
MBRX
16 hedge funds and large institutions have $5.26M invested in Moleculin Biotech in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 5 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
0.22% less ownership
Funds ownership: 10.57% → 10.34% (-0.22%)
11% less funds holding
Funds holding: 18 → 16 (-2)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
48% less capital inflows, than outflows
Capital inflows: $138K | Capital outflows: $264K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$45.9K |
| 2 |
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$22.9K |
| 3 |
State Street
Boston,
Massachusetts
|
+$22.9K |
| 4 |
Envestnet Asset Management
Chicago,
Illinois
|
+$11.5K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$11.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Virtu Financial
New York
|
-$87K |
| 2 |
Occudo Quantitative Strategies
Fort Lauderdale,
Florida
|
-$41K |
| 3 |
Two Sigma Securities
New York
|
-$41K |
| 4 |
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$37K |
| 5 |
BlackRock
New York
|
-$22.9K |
MBRX Hedge Fund Activity: Q1 2022 in Review
16 of the 6,364 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q1 2022, worth a combined $5.26M — down 6.3% from $5.61M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of MBRX and 3 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 4 added.
The largest buyer was Renaissance Technologies, adding an estimated $45.9K. The largest seller was Virtu Financial, exiting entirely with an estimated $87K sold.
- 16 institutional investors held Moleculin Biotech (MBRX) as of Q1 2022, down from 18 in Q4 2021.
- Funds reported $5.26M of Moleculin Biotech stock for Q1 2022, down 6.3% quarter-over-quarter.
- 3 funds opened new Moleculin Biotech positions in Q1 2022 and 5 closed out, a net change of -2 holders.
- The largest Moleculin Biotech buyer in Q1 2022 was Renaissance Technologies, an estimated $45.9K added.
- The largest Moleculin Biotech seller in Q1 2022 was Virtu Financial, an estimated $87K sold.
Based on aggregated 13F filings for Q1 2022.